TheraRadar
← Back
Data updated: May 24, 2026

UPSHER SMITH LABS

Generics

UPSHER SMITH LABS is a generic drug manufacturer focused on Neurology, Cardiovascular, Dermatology. Key products include QUDEXY XR.

1974
Since
64
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 33%
6 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Cardiovascular 25%
6 drugs
Dermatology 17%
4 drugs
Metabolic 13%
3 drugs
Respiratory 13%
3 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

2
Phase 3
1
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • QUDEXY XR leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling